Sohn Minji, Kim Keumji, Uddin Md Jamal, Lee Gayoung, Hwang Inah, Kang Hyeji, Kim Hyunji, Lee Jung Hwa, Ha Hunjoo
Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Korea.
Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Korea
Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F323-F334. doi: 10.1152/ajprenal.00596.2015. Epub 2016 Jul 27.
Fenofibrate activates not only peroxisome proliferator-activated receptor-α (PPARα) but also adenosine monophosphate-activated protein kinase (AMPK). AMPK-mediated cellular responses protect kidney from high-fat diet (HFD)-induced injury, and autophagy resulting from AMPK activation has been regarded as a stress-response mechanism. Thus the present study examined the role of AMPK and autophagy in the renotherapeutic effects of fenofibrate. C57BL/6J mice were divided into three groups: normal diet (ND), HFD, and HFD + fenofibrate (HFD + FF). Fenofibrate was administered 4 wk after the initiation of the HFD when renal injury was initiated. Mouse proximal tubule cells (mProx24) were used to clarify the role of AMPK. Feeding mice with HFD for 12 wk induced insulin resistance and kidney injury such as albuminuria, glomerulosclerosis, tubular injury, and inflammation, which were effectively inhibited by fenofibrate. In addition, fenofibrate treatment resulted in the activation of renal AMPK, upregulation of fatty acid oxidation (FAO) enzymes and antioxidants, and induction of autophagy in the HFD mice. In mProx24 cells, fenofibrate activated AMPK in a concentration-dependent manner, upregulated FAO enzymes and antioxidants, and induced autophagy, all of which were inhibited by treatment of compound C, an AMPK inhibitor. Fenofibrate-induced autophagy was also significantly blocked by AMPKα1 siRNA but not by PPARα siRNA. Collectively, these results demonstrate that delayed treatment with fenofibrate has a therapeutic effect on HFD-induced kidney injury, at least in part, through the activation of AMPK and induction of subsequent downstream effectors: autophagy, FAO enzymes, and antioxidants.
非诺贝特不仅能激活过氧化物酶体增殖物激活受体-α(PPARα),还能激活腺苷单磷酸激活的蛋白激酶(AMPK)。AMPK介导的细胞反应可保护肾脏免受高脂饮食(HFD)诱导的损伤,而由AMPK激活引起的自噬被视为一种应激反应机制。因此,本研究探讨了AMPK和自噬在非诺贝特肾脏治疗作用中的作用。将C57BL/6J小鼠分为三组:正常饮食(ND)组、HFD组和HFD + 非诺贝特(HFD + FF)组。在开始给予HFD 4周后,即肾脏损伤开始时给予非诺贝特。使用小鼠近端肾小管细胞(mProx24)来阐明AMPK的作用。给小鼠喂食HFD 12周会诱导胰岛素抵抗和肾脏损伤,如蛋白尿、肾小球硬化、肾小管损伤和炎症,而非诺贝特可有效抑制这些损伤。此外,非诺贝特治疗导致HFD小鼠肾脏AMPK激活、脂肪酸氧化(FAO)酶和抗氧化剂上调以及自噬诱导。在mProx24细胞中,非诺贝特以浓度依赖性方式激活AMPK,上调FAO酶和抗氧化剂,并诱导自噬,而这些作用均被AMPK抑制剂化合物C处理所抑制。非诺贝特诱导的自噬也被AMPKα1 siRNA显著阻断,但未被PPARα siRNA阻断。总体而言,这些结果表明,非诺贝特延迟治疗对HFD诱导的肾脏损伤具有治疗作用,至少部分是通过激活AMPK并诱导随后的下游效应物:自噬、FAO酶和抗氧化剂来实现的。